Previous 10 | Next 10 |
Flex Pharma (NASDAQ: FLKS ): Q4 GAAP EPS of -$0.11. More news on: Flex Pharma, Earnings news and commentary, Healthcare stocks news, , Read more ...
Flex Pharma, Inc. (NASDAQ: FLKS), today announced its financial results for the three months and fiscal year ended December 31, 2018. On January 3, 2019, Flex Pharma (the "Company") and Salarius Pharmaceuticals, LLC ("Salarius") entered into an Agreement and Plan of Merger (the "Merg...
Kicking off 2019 with a new merger is Flex Pharma (NASDAQ:FLKS), a Boston, Massachusetts-based biotechnology company. And it’s paying off. FLKS stock is up nearly 40% today, making it a Yahoo Finance trending ticker of the day. Flex Pharma, the FLKS Stock, and a New Merger On Fri...
CORAL GABLES, FL / ACCESSWIRE / January 4, 2019 / As we close out the week of the first few days of the new year, The health care industry is booming with companies determined to use inventive approaches to develop quality treatment options for patients around the world. As demand for qual...
Flex Pharma (NASDAQ: FLKS ) and Salarius Pharmaceuticals, LLC, have entered into a merger agreement under which later will merge with a wholly-owned subsidiary of Flex Pharma. More news on: Flex Pharma, Healthcare stocks news, Stocks on the move, Read more ...
– Lead Candidate in Clinical Trial for Treating Ewing Sarcoma – – Salarius Completes $6.4 Million Private Placement – – Conference Call and Live Audio Webcast Scheduled for Today at 9:00 a.m. ET – Flex Pharma, Inc . (NASDAQ: FLKS), ...
Flex Pharma (NASDAQ: FLKS ): Q3 GAAP EPS of -$0.15. More news on: Flex Pharma, Earnings news and commentary, Healthcare stocks news, , Read more ...
Flex Pharma, Inc. (NASDAQ: FLKS), today announced its financial results for the three months ended September 30, 2018. On June 13, 2018, the Company announced that it was ending its ongoing Phase 2 clinical trial investigations of FLX-787 in Motor Neuron Disease (MND), which primarily ...
CORAL GABLES, FL / ACCESSWIRE / October 29,2018 / Frost & Sullivan will be hosting a Growth Innovation Leadership (GIL) briefing titled "2019 Healthcare Predictions Unleashed - Growth Opportunities, Technology, and Trends." The firm already states that Globally, 2019 will be a year of ...
NEW YORK, NY / ACCESSWIRE / October 22, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Flex Pharma, Inc. (NASDAQ: FLKS) a biotechnology company focused on develop...
News, Short Squeeze, Breakout and More Instantly...
FTSE Lujain Kuwait Shariah Index Company Name:
FLKS Stock Symbol:
NASDAQ Market:
FTSE Lujain Kuwait Shariah Index Website:
Flex Pharma, Inc. (Nasdaq: FLKS) announced that its Board of Directors today declared a special dividend on the Company’s common stock of one right per share of outstanding common stock. The rights will be paid on July 19, 2019 to shareholders of record as of close of business on July ...
Flex Pharma, Inc. (Nasdaq: FLKS) today announced that its stockholders approved all proposals relating to its planned merger with Salarius Pharmaceuticals, LLC at Flex Pharma’s special meeting of stockholders. Flex Pharma will file a Form 8-K to disclose detailed voting results for eac...
Flex Pharma, Inc. (Nasdaq: FLKS) today announced that on or about June 27, 2019 it will mail a supplement (the “Supplement”) to its proxy materials to provide stockholders with updated information regarding brokers’ discretionary authority to vote stockholders’ sha...